美国癌症委员会淋巴结采样标准与肺切除术后肿瘤学结局
该研究基于前瞻性机构数据库,纳入新标准实施前的9289例临床I-III期肺切除病例,评估每例采样3个N2站和1个N1站是否符合标准,并与肿瘤学结局的关系。符合该标准的3048例(33%)淋巴结升级率和院内并发症率更高,局部/远处复发在各分期均无显著改善;总生存仅在临床III期患者中改善。
要点
- 符合3(N2)1(N1)标准者淋巴结升级率更高:21% vs 13%,OR 1.32(95%CI 1.14-1.51;P<.001)。
- 符合标准的患者院内并发症更高:34% vs 27%,OR 1.17(95%CI 1.05-1.30;P=.004)。
- 临床III期符合标准者总生存改善:HR 0.85(95%CI 0.74-0.97;P=.02);I、II期相似。
核心结论
- 采样3个N2站和1个N1站在临床I或II期患者中与淋巴结升级和并发症增加相关,但与复发或死亡率降低无关。
- 符合标准的临床III期患者总生存改善。
- 需进一步研究以确定异质性肺癌患者的理想淋巴结采样策略。
研究设计与样本
- 前瞻性机构数据库查询,纳入新标准实施前的临床I-III期肺切除病例。
- 共9289例肺切除,3048例(33%)符合3(N2)1(N1)标准(指南一致),6241例(67%)不符合。
- 采用多变量模型评估指南一致性与结局关系,并按分期分层。
主要发现
- 指南一致组淋巴结升级率高于不一致组:21% vs 13%;OR 1.32(95%CI 1.14-1.51;P<.001)。
- 指南一致组院内并发症率高于不一致组:34% vs 27%;OR 1.17(95%CI 1.05-1.30;P=.004)。
- 辅助全身治疗给药两组相似:19% vs 13%;OR 1.09(95%CI 0.95-1.24;P=.2;98%为化疗)。
- 临床I、II、III期各亚组中,指南一致性均未显著改善局部和远处复发。
- 总生存:临床I、II期两组相似;临床III期指南一致组改善,HR 0.85(95%CI 0.74-0.97;P=.02)。
关键数值与推荐
- 指南一致定义为采样3个纵隔(N2)和1个肺门(N1)淋巴结站,即3(N2)1(N1)。
- 指南一致组3048例(33%),非一致组6241例(67%),共9289例肺切除。
- 临床III期指南一致组总生存HR 0.85(95%CI 0.74-0.97;P=.02)。
临床怎么用
- 对于临床I或II期肺切除患者,采用3(N2)1(N1)采样与更高的淋巴结升级率和并发症率相关,但未显示复发或死亡率降低。
- 对于临床III期患者,指南一致采样与总生存改善相关(HR 0.85)。
- 原文指出需进一步研究以确定异质性肺癌患者的理想淋巴结采样策略。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The newest Commission on Cancer standards recommend sampling 3 mediastinal and 1 hilar lymph node stations, 3 (N2) 1 (N1), for lung cancer resections. However, the relationship between the Commission on Cancer standards and outcomes has not been thoroughly investigated. METHODS: A prospective institutional database was queried for clinical stage I-III lung resections before the implementation of the new standards. The relationship between the 3 (N2) 1 (N1) standard ("guideline concordant") and outcomes (upstaging, complications, receipt of adjuvant therapy, locoregional/distant recurrence, and survival) was assessed with multivariable models and stratified by stage. RESULTS: Of 9289 pulmonary resections, 3048 (33%) were guideline concordant and 6241 (67%) were not. Compared with nonconcordant, those that were guideline concordant had higher rates of nodal upstaging (21% vs 13%; odds ratio [OR], 1.32 [95% CI, 1.14-1.51]; P < .001) and in-hospital complications (34% vs 27%; OR, 1.17 [95% CI, 1.05-1.30]; P = .004) but similar adjuvant systemic therapy administration (19% vs 13%; OR, 1.09 [95% CI, 0.95-1.24]; P = .2; 98% chemotherapy). Locoregional and distant recurrences were not significantly improved with guideline concordance across clinical stage I, II, and III subsets. Overall survival was similar in clinical stages I and II, but improved survival was observed for guideline concordant clinical stage III patients (hazard ratio, 0.85 [95% CI, 0.74-0.97]; P = .02). CONCLUSIONS: Sampling 3 (N2) 1 (N1) was associated with increased upstaging and complications but not with decreased recurrence or mortality in clinical stage I or II patients. Survival was improved for concordant, clinical stage III patients. Further study is indicated to determine the ideal lymph node sampling strategy across heterogeneous lung cancer patients.
引用
- Resio BJ, Tan KS, Skovgard M, et al. Commission on Cancer Standards for Lymph Node Sampling and Oncologic Outcomes After Lung Resection. Ann Thorac Surg. 2024. PMID: 39299477. doi:10.1016/j.athoracsur.2024.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。